Shown is the ideal process for translation of risk assessment models (RAMs) developed in patients with MM into clinical practice. Three RAMs, 2 existing and 1 newly proposed, are currently available for predicting VTEs in patients with MM. These risk factors are common to the 3 RAMs: race/ethnicity and history of VTEs. Use of IMiDs is common to PRISM and IMPEDE VTE; previous surgery is common to PRISM and SAVED; and use of dexamethasone-doxorubicin (DMX/DOX) is common to SAVED and IMPEDE VTE. PRISM includes a new disease-specific risk factor: abnormal metaphase cytogenetics. ∗The SAVED score was derived only from patients receiving IMiDs. BMI, body mass index; ESA, erythropoiesis-stimulating agent.